Highlights

  • OncoSil Medical (ASX:OSL) secured U.S. FDA Humanitarian Device Exemption approval for the OncoSil device for eligible distal cholangiocarcinoma patients.
  • The company raised $5.6 million from major institutional investors in September 2026, lifting pro-forma cash and cash equivalents to $12.1 million.
  • OncoSil reached its 100th patient treatment in Spain, where it had 11 active treatment sites as of September 2026.
  • At the time of writing this article, OncoSil Medical (ASX:OSL) was trading at AUD 0.805, up 10.27% during today’s trading session.

At the time of writing this article, OncoSil Medical (ASX:OSL) was trading at AUD 0.805, up 10.27% during today’s trading session. The Australian medical device company is focused on interventional oncology and has developed a targeted internal radiation treatment designed for difficult-to-treat cancers. During 2026, the company advanced regulatory approvals in Australia and the United States while expanding treatment activity in Europe and preparing for a broader commercial phase.

Company Business

OncoSil Medical develops the OncoSil device, a single-use brachytherapy system that delivers a predetermined dose of Beta radiation directly into cancerous tissue using Phosphorous-32 microparticles. The device is implanted into the tumour under image-guided procedures, allowing radiation to be concentrated within targeted tissue.

Outside the United States, the OncoSil device is approved in several jurisdictions for use in patients with unresectable locally advanced pancreatic cancer alongside specified chemotherapy. Regulatory approvals cover more than 30 countries, including Australia, the European Union, United Kingdom, Saudi Arabia, Türkiye and Israel. Commercial treatments have already taken place across a number of European markets.

The company is also building a separate U.S. commercial pathway following regulatory clearance for use of OncoSil in eligible patients with distal cholangiocarcinoma, a rare form of bile duct cancer.

Recent Development

A key development during 2026 was U.S. FDA approval of the OncoSil device under the Humanitarian Device Exemption pathway for patients with unresectable, non-metastatic distal cholangiocarcinoma as an adjunct to systemic therapy. The approval provides U.S. Marketing authorisation for this indication and allows OncoSil Medical to progress preparations for a focused commercial launch.

Under the approval framework, initial U.S. use is expected to be restricted to a maximum of five treatment centres as part of an FDA-required post-approval study. The prospective study is expected to enrol 30 patients and follow participants for up to 24 months. OncoSil has indicated that its U.S. launch is targeted for the second half of FY27.

Commercial activity has also continued in Europe. In September 2026, OncoSil reported that its 100th patient in Spain had been treated with the device. The company had 11 active Spanish treatment sites at that time and was focusing on increasing utilisation within its existing hospital network.

Financial Performance and Sector Context

OncoSil remains in a commercialisation and market-development phase, meaning funding requirements are closely linked to regulatory programs, manufacturing, clinical studies and the expansion of treatment networks.

In September 2026, the company secured commitments for $5.6 million from three institutional investors. The funding comprised a $4.0 million share Placement and approximately $1.6 million from the Early Exercise of listed options. Based on cash of $6.5 million at 30 June 2026 and the new funding, OncoSil reported pro-forma cash and cash equivalents of approximately $12.1 million.

The additional Capital is intended to support commercialisation in the United States and Australia following regulatory approvals. The company has also identified Manufacturing commencement, European regulatory filings and clinical study activity among its FY27 priorities.

On the clinical side, updated TRIPP-FFX study data presented in July 2026 included a per-protocol median overall survival of 21.3 months for patients treated with OncoSil plus FOLFIRINOX. The study had previously met its co-primary endpoints relating to safety, tolerability and local disease control.

Risks to Consider

OncoSil Medical remains exposed to regulatory, clinical, reimbursement and commercialisation risks. Uptake depends on clinician adoption, treatment-centre activation and patient eligibility. Expansion into the United States also requires execution of the post-approval study, establishment of treatment sites and progress on reimbursement arrangements.

The Business must also manage manufacturing capacity and regulatory compliance as commercial activity expands. Funding requirements remain relevant while the company develops revenue-generating markets and continues clinical and regulatory programs.

What to Watch Next

Key developments to monitor include preparations for the U.S. launch of the OncoSil device, progress with reimbursement pathways and activation of the initial U.S. treatment centres.

Investors may also monitor utilisation across the 11 active sites in Spain, expansion elsewhere in Europe and Australia, manufacturing activity in Sydney and further clinical evidence from the company’s studies and registries. The timing of additional European regulatory filings and progress of the planned FDA post-approval study will also be relevant during FY27.

Key Insights

OncoSil Medical entered FY27 with regulatory approvals in Australia and the United States, an expanding European treatment network and additional capital for commercialisation activities. The company’s recent developments have shifted attention toward execution, including treatment-centre activation, reimbursement, manufacturing and increased utilisation of the OncoSil device.

Its $12.1 million pro-forma cash position following the September funding provides additional resources for these activities, while clinical and regulatory milestones will remain important indicators of progress.